Anixa Biosciences (ANIX) to Release Quarterly Earnings on Wednesday

Anixa Biosciences (NASDAQ:ANIX) will likely be posting its Q3 2026 results before the market opens on Wednesday, September 9th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Wednesday, September 16, 2026 at 4:00 PM ET.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. On average, analysts expect Anixa Biosciences to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Anixa Biosciences Stock Performance

NASDAQ ANIX opened at $3.07 on Tuesday. The firm’s fifty day moving average price is $3.36 and its two-hundred day moving average price is $2.99. The firm has a market capitalization of $104.44 million, a P/E ratio of -9.90 and a beta of 0.51. Anixa Biosciences has a 1 year low of $2.32 and a 1 year high of $5.46.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the stock. Zacks Research downgraded shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Wall Street Zen upgraded shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. HC Wainwright reissued a “buy” rating on shares of Anixa Biosciences in a report on Friday, June 12th. Citigroup reiterated a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Finally, D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a report on Tuesday, June 30th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $8.50.

Insider Buying and Selling

In other Anixa Biosciences news, CEO Amit Kumar bought 21,000 shares of the stock in a transaction dated Friday, June 12th. The shares were bought at an average cost of $2.50 per share, for a total transaction of $52,500.00. Following the purchase, the chief executive officer directly owned 630,812 shares of the company’s stock, valued at approximately $1,577,030. This trade represents a 3.44% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have bought 50,024 shares of company stock valued at $148,971. Company insiders own 26.40% of the company’s stock.

Hedge Funds Weigh In On Anixa Biosciences

Hedge funds have recently made changes to their positions in the stock. 683 Capital Management LLC purchased a new stake in Anixa Biosciences in the 4th quarter worth approximately $355,000. ExodusPoint Capital Management LP purchased a new position in shares of Anixa Biosciences during the 4th quarter valued at $293,000. Susquehanna International Group LLP increased its holdings in shares of Anixa Biosciences by 378.4% in the third quarter. Susquehanna International Group LLP now owns 80,387 shares of the company’s stock worth $265,000 after purchasing an additional 63,584 shares during the period. Virtu Financial LLC purchased a new stake in shares of Anixa Biosciences in the fourth quarter worth $161,000. Finally, State Street Corp raised its position in shares of Anixa Biosciences by 32.0% in the fourth quarter. State Street Corp now owns 159,040 shares of the company’s stock worth $496,000 after buying an additional 38,540 shares in the last quarter. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.